Enduring Activity
View Archive

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology, Inc.

Integrating the Evidence for Risk-Based Individualization of Adjuvant Therapy for HER2-Positive Breast Cancer

Integrating the Evidence for Risk-Based Individualization of Adjuvant Therapy for HER2-Positive Breast Cancer

Friday, March 5, 2021

Live, Interactive Virtual Conference!

6:00 PM - 7:30 PM EST


Over the past few years, results from pivotal trials and new regulatory approvals have expanded treatment options for patients with early-stage HER2-positive (HER2+) breast cancer, and treatment paradigms are evolving rapidly. New approaches include dual-targeting of the HER2 receptor, extended HER2-targeted adjuvant therapy, and adjuvant therapy for patients with HER2+ residual disease following preoperative treatment. With all of these options comes the challenge of applying these data in clinical practice, particularly matching treatment strategies to individual patients based on tumor and patient characteristics to optimize outcomes.

Integrating the Evidence for Risk-Based Individualization of Adjuvant Therapy for HER2-Positive Breast Cancer is a continuing medical education-certified virtual webcast that will feature a mix of didactic presentations from prominent experts in the field, combined with case discussions to illustrate the application of the latest data in real-world clinical scenarios. Topics will include assessing HER2 status and estimation of recurrence risk in early-stage disease, current data from adjuvant trials of HER2-targeted treatments, and management of potential adverse events associated with therapies. Additionally, this program includes a “Bring Your Own Case!” session, where you can gain input from experts about any case or questions you may have regarding the management of early-stage HER2+ breast cancer.

Benefits of Attending

  • Hear experts discuss the latest data from clinical trials investigating adjuvant therapies for HER2+ breast cancer in the context of clinical decision-making for patients.
  • Gain insights into strategies for individualizing the treatment of patients with early-stage HER2+ breast cancer.
  • Learn how to manage adverse events associated with HER2-targeted therapies effectively.
  • You can submit your own challenging clinical case for input from the expert faculty.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology, Inc.

Target Audience

This educational activity is directed toward medical oncologists, surgeons, pathologists, and fellows attending the 38th Annual Miami Breast Cancer Conference®. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Review expert guidelines regarding HER2 testing and characterization of HER2 status, as well as criteria for risk assessment;
  • Discuss adjuvant treatment strategies to reduce recurrence risk among patients with high-risk HER2+ breast cancer;
  • Integrate evidence from landmark clinical trials in the adjuvant and neoadjuvant settings into individualized treatment plans for patients with early-stage HER2+ breast cancer; and
  • Implement strategies for mitigating and managing adverse events associated with HER2-targeted therapies in order to minimize them and maintain treatment efficacy.

Hot Topics

  • Assessing HER2 status and recurrence risk in early-stage breast cancer;
  • Individualizing adjuvant therapy for early-stage HER2+ breast cancer; and
  • Preventing and managing adverse events associated with HER2-targeted therapies.

Program Chair

Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701

Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By